A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
Official title: The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension
Funded at Icahn School of Medicine at Mount Sinai · NIH-11418121 · Data updated 2026-11-12
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 15, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $335,984 |
| NIH project number | 5R33HL163755-03 |
| Project ID | NIH-11418121 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with severe pulmonary arterial hypertension with right‑heart strain or failure who are not well controlled by medicines and who may be awaiting lung transplant.
✕Less likely to help
Patients whose symptoms are caused mainly by left‑sided heart disease, those with active infections, or who cannot tolerate catheter placement are unlikely to benefit.
What this research studies
You would be offered a device that uses two channels and sits across the upper chambers of the heart to divert blood and reduce strain on the right ventricle. The team plans to design a way to anchor the catheter for long‑term use and build in sensors to monitor and control blood flow. Work will start with lab and animal testing and progress toward carefully monitored human use to check safety and function. The hope is this approach could keep you stable long enough for medical treatment to work or while waiting for a lung transplant.
Why it matters
Potential benefit: If successful, this device could lower pressure on the right heart and lungs, prolong survival, and give patients more time to respond to medicines or reach transplant.
How similar studies have gone: While other right‑heart support devices and interatrial approaches exist, this specific biatrial dual‑lumen catheter design is novel and largely untested in humans.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Benza, Raymond Louis — Icahn School of Medicine at Mount Sinai
- Study coordinator: Benza, Raymond Louis
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
-
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
A 3-center, placebo-controlled study tests whether daily 10 mg empagliflozin for 24 weeks can help heart function and other outcomes in people with PAH.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.